The Food and Drug Administration on Tuesday kicked off an effort to use AI and other data science tools to monitor clinical trials in real time and cut down review times for new drugs.
Why it matters: Agency leaders portrayed the move as a major step toward keeping U.S. biomedical research competitive against countries like China.
Supreme Court justices on Wednesday will hear arguments in a patent case that could change the way generic drug companies market and label copycat products.
Why it matters: At the heart of the case is whether efforts to lower health costs through generic competition are undercutting patent protections that brand-name drugmakers say are essential for innovation.
The Trump administration is reviving charges that federal officials covered up the origins of COVID-19 by indicting a former top adviser to Anthony Fauci.
